11. Kamath SM, Stoecker BJ, Davis-Whitenack ML, Smith MM, Adeleye BO, Sangiah S. Absorption, retention and urinary excretion of chromium-51 in rats pretreated with indomethacin and dosed with dimethylprostaglandin E2
, misoprostol or prostacyclin. J Nutr. 1997, 127(3):478-482.
12. National Business Journal. Supplement Business Report. National Business Journal. 2017;71-73.
13. Federal Trade Commission. Docket No. C-3758 Decision and Order. July 1997. Accessed May 7, 2020. www . ftc . gov / sites / default / files / documents / cases / 1997 / 07 / nutrit2 . htm
14. Lukaski HC. Effects of chromium as a nutritional supplement. In: Vincent JB, ed. The Nutritional Biochemistry of Chromium(III). 2nd ed. Elsevier; 2019:61-77. doi:10 . 1016 / B978 - 0 - 444 - 64121 - 2 . 00002 - 7
15. Vincent JB. Is chromium pharmacologically relevant? J Trace Elem Med Biol. 2014; 28(4):397-405. doi:10 . 1016 / j . jtemb . 2014 . 06 . 020
16. Costello RB, Dwyer JT, Merkel JM. Chromium supplements in health and disease. In: Vincent JB, ed. The Nutritional Biochemistry of Chromium(III). 2nd ed. Elsevier; 2019:219- 249. doi:10 . 1016 / B978 - 0 - 444 - 64121 - 2 . 00007 - 6
17. US Food and Drug Administration. Qualified Health Claims: Letter of Enforcement Discretion—Chromium Picolinate and Insulin Resistance (Docket No. 2004Q-0144). US Department of Health and Human Services website. August 2005. Accessed May 7, 2020. http://wayback . archive - it . org / 7993 / 20171114183739 / https://www . fda . gov / Food / IngredientsPackagingLabeling / LabelingNutrition / ucm073017 . htm
18. American Diabetes Association. Lifestyle management: standards of medical care in diabetes—2019. Diabetes. 2019;42(suppl 1):S46-S60. doi:10 . 2337 / dc19 - S005
160 HEALTH PROFESSIONAL’S GUIDE TO DIETARY SUPPLEMENTS